IRB #

STUDY00016300

Title

A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of
Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare the safety and effects of the combination of pembrolizumab, a research study drug, and axitinib with sunitinib alone on participants and their metastatic renal cell carcinoma.

Medical Condition(s)

Metastatic renal cell carcinoma

Eligibility Criteria

18 years or older with diagnosed metastatic renal cell carcinoma. Further exams, tests, and procedures will be done to confirm eligibility.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

For as long as the participant is seeing benefit

Minors Included

No

Contact

Knight Clinical Trials
trials@ohsu.edu

Sponsor

Merck Sharp & Dohme Corp

Recruitment End

11/12/2020

Compensation Provided

No


Go Back